Dr. Murali K. Divi has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
DIVISLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty 100 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Murali K. Divi, the promoter of Divi's Laboratories, has submitted a disclosure to the exchange under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires promoters to inform the exchange about any encumbrance (pledge) created on their shares or any change in the extent of such encumbrance. The disclosure indicates a change in the pledging status of shares held by the promoter. The exact direction of the change (new pledge, release, or invocation) is not specified in the headline, but the filing itself confirms an active pledge-related event involving the promoter's stake. Shareholders should refer to the detailed disclosure on the BSE/NSE portal for exact numbers.
Disclosure of a change in promoter share encumbrance is material — it may signal promoter borrowing against shares, which investors should track closely as it reflects leverage at the promoter level and could affect sentiment if pledge levels rise further.